ArticleMayo Clinic proceedings. Innovations, quality & outcomes2026
Differences in Itch Quality Between Interleukin-31 and Thymus and Activation-Regulated Chemokine of Japanese Atopic Dermatitis.
Article in Mayo Clinic proceedings. Innovations, quality & outcomes, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To elucidate the relationships among various itch qualities, blood biomarkers, and patient-reported outcome measures (PROMs) in atopic dermatitis (AD), we characterized 10 qualities of itch (QoIs) in adult Japanese patients with AD and examined their associations with blood biomarkers as well as objective and subjective clinical measures. Patients and Methods: The QoI was assessed by a translated 10-item questionnaire. The relationship among each QoI and blood biomarkers (including interleukin [IL]-31, thymus and activation-regulated chemokine [TARC], and lactate dehydrogenase levels; differential white blood cell counts, including eosinophil, basophil, and neutrophil relative counts; and total immunoglobulin E levels); PROMs, such as visual analog scale and patient-oriented eczema measure; and objective measures, such as eczema area and severity index, was evaluated. Results: Patients with AD frequently suffered from a sensation similar to crawling like ant (crawling) and stinging and burning sensations. Crawling was positively correlated with serum IL-31 levels but not serum TARC level. Stinging and stabbing sensations were positively correlated with serum TARC level but not with serum IL-31 levels. Stinging, stabbing, and burning sensations were correlated with PROMs and eczema area and severity index. Our limitation is that other cytokines, such as IL-4 and IL-13, were not measured. Conclusion: The QoI in Japanese patients with AD could be classified into IL-31-related and TARC-related types. Our findings suggest relationships between crawling and IL-31 and between stinging and stabbing and TARC in Japanese patients with AD.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.